PT2794654T - Anticorpos anti-phf-tau e suas utilizações - Google Patents

Anticorpos anti-phf-tau e suas utilizações

Info

Publication number: PT2794654T
Authority: PT; Portugal
Prior art keywords: phf; tau antibodies; tau; antibodies
Prior art date: 2011-12-20

Application number

PT12859920T

Other languages

English (en)

Inventor

Mercken Marc

Alderfer Christopher

Janecki Dariusz

Liu Xuesong

Murdock Melissa

Wu Sheng-Jiun

Vandermeeren Marc

Malia Thomas

Original Assignee

Janssen Biotech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-12-20

Filing date

2012-12-19

Publication date

2019-09-10

2012-12-19 Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc

2019-09-10 Publication of PT2794654T publication Critical patent/PT2794654T/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PT12859920T 2011-12-20 2012-12-19 Anticorpos anti-phf-tau e suas utilizações PT2794654T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161577817P	2011-12-20	2011-12-20

Publications (1)

Publication Number	Publication Date
PT2794654T true PT2794654T (pt)	2019-09-10

Family

ID=48669693

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT12859920T PT2794654T (pt)	2011-12-20	2012-12-19	Anticorpos anti-phf-tau e suas utilizações

Country Status (34)

Country	Link
US (4)	US9371376B2 (pt)
EP (2)	EP2794654B1 (pt)
JP (4)	JP6306513B2 (pt)
KR (1)	KR101991681B1 (pt)
CN (2)	CN107226863B (pt)
AU (2)	AU2012359039B2 (pt)
BR (1)	BR112014015323B1 (pt)
CA (2)	CA3234629A1 (pt)
CO (1)	CO6980627A2 (pt)
CY (1)	CY1121862T1 (pt)
DK (1)	DK2794654T3 (pt)
EA (1)	EA027975B1 (pt)
EC (1)	ECSP14005975A (pt)
ES (1)	ES2738007T3 (pt)
GT (1)	GT201400127A (pt)
HK (2)	HK1203520A1 (pt)
HR (1)	HRP20191342T1 (pt)
HU (1)	HUE045656T2 (pt)
IL (3)	IL233051B (pt)
LT (1)	LT2794654T (pt)
MX (1)	MX350311B (pt)
MY (2)	MY186066A (pt)
NI (1)	NI201400061A (pt)
NZ (1)	NZ626269A (pt)
PH (1)	PH12014501427B1 (pt)
PL (1)	PL2794654T3 (pt)
PT (1)	PT2794654T (pt)
RS (1)	RS59024B1 (pt)
SG (1)	SG11201403106SA (pt)
SI (1)	SI2794654T1 (pt)
TR (1)	TR201910720T4 (pt)
UA (1)	UA114902C2 (pt)
WO (1)	WO2013096380A2 (pt)
ZA (1)	ZA201405317B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2794654B1 (en) *	2011-12-20	2019-05-22	Janssen Biotech, Inc.	Anti-phf-tau antibodies and their uses
WO2014008404A1 (en)	2012-07-03	2014-01-09	Washington University	Antibodies to tau
SI2885010T1 (sl)	2012-08-16	2020-07-31	Ipierian, Inc.	Metode zdravljenja tauopatije
US8980270B2 (en)	2013-01-18	2015-03-17	Ipierian, Inc.	Methods of treating a tauopathy
US10400018B2 (en)	2014-02-14	2019-09-03	Ipierian, Inc.	Tau peptides, anti-tau antibodies, and methods of use thereof
ZA201608812B (en) *	2014-06-26	2019-08-28	Janssen Vaccines & Prevention Bv	Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
AU2015279089B2 (en) *	2014-06-26	2021-01-28	Janssen Vaccines & Prevention B.V.	Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
TW202136296A (zh)	2014-06-27	2021-10-01	美商Ｃ２Ｎ醫療診斷有限責任公司	人類化抗-tau抗體
WO2016112078A2 (en) *	2015-01-08	2016-07-14	Janssen Biotech, Inc.	Anti-phf-tau antibodies and their uses
JO3576B1 (ar)	2015-02-26	2020-07-05	Lilly Co Eli	أجسام مضادة لـ tau واستخداماتها
AU2016270858B2 (en)	2015-06-05	2022-04-28	Ac Immune Sa	Anti-Tau antibodies and methods of use
MA41670A1 (fr) *	2015-07-06	2018-05-31	Ucb Biopharma Sprl	Anticorps se liant a tau
TN2017000543A1 (en) *	2015-07-06	2019-04-12	Ucb Biopharma Sprl	Tau-binding antibodies
WO2017189963A1 (en) *	2016-04-29	2017-11-02	Voyager Therapeutics, Inc.	Compositions for the treatment of disease
EP3496750A2 (en)	2016-08-09	2019-06-19	Eli Lilly and Company	Combination therapy
UA128383C2 (uk)	2016-12-07	2024-07-03	Дженентек, Інк.	Антитіло до тау-білка та спосіб його застосування
JP2020511937A (ja)	2016-12-07	2020-04-23	ジェネンテック，インコーポレイテッド	抗ｔａｕ抗体及び使用方法
KR20190134997A (ko)	2017-02-17	2019-12-05	데날리 테라퓨틱스 인크.	항-tau 항체 및 이의 사용 방법
JOP20180014A1 (ar)	2017-02-27	2019-01-30	Teijin Pharma Ltd	جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه
JOP20180021A1 (ar) *	2017-03-16	2019-01-30	Janssen Biotech Inc	الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
CN111630064B (zh)	2017-10-16	2023-06-27	卫材R&D管理有限公司	抗Tau抗体及其用途
AU2019232631A1 (en) *	2018-03-05	2020-09-24	Janssen Pharmaceutica Nv	Anti-PHF-tau antibodies and uses thereof
SG11202008574VA (en)	2018-03-05	2020-10-29	Janssen Pharmaceutica Nv	Assays to detect neurodegeneration
SG11202008098TA (en) *	2018-03-28	2020-10-29	Axon Neuroscience Se	Antibody-based methods of detecting and treating alzheimer's disease
CN112543648A (zh)	2018-07-31	2021-03-23	伊莱利利公司	组合疗法
CR20220505A (es) *	2020-04-08	2023-05-31	Janssen Biotech Inc	Anticuerpos anti-phf-tau y usos de estos
IL297200A (en)	2020-04-15	2022-12-01	Voyager Therapeutics Inc	tau binding compounds
IL299292A (en)	2020-06-25	2023-02-01	Merck Sharp & Dohme Llc	High-affinity antibodies to tau phosphorylated at serine 413
JP2023554382A (ja)	2020-12-16	2023-12-27	ボイジャーセラピューティクスインコーポレイテッド	タウ結合化合物
JP2024513172A (ja) *	2021-03-26	2024-03-22	ヤンセンバイオテツク，インコーポレーテツド	対らせん状細線維タウに対するヒト化抗体及びその使用
TW202304974A (zh) *	2021-03-26	2023-02-01	美商健生生物科技公司	抗tau抗體及其用途
WO2023250388A1 (en)	2022-06-22	2023-12-28	Voyager Therapeutics, Inc.	Tau binding compounds
WO2024059739A1 (en)	2022-09-15	2024-03-21	Voyager Therapeutics, Inc.	Tau binding compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
WO1993008302A1 (en) *	1991-10-25	1993-04-29	Itt Automotive Europe Gmbh	Monoclonal antibodies directed against the microtubule-associated protein tau
DK0737208T3 (da)	1993-12-21	2006-11-27	Innogenetics Nv	Monoklonale antistoffer, der er specifikke for PHF-tau, hybridomaer, der secernerer dem, og antigen-genkendelse for disse antistoffer og deres anvendelsesmuligheder
US6121003A (en) *	1994-07-29	2000-09-19	Innogentics N.V.	Monoclonal antibodies specific for an epitope of phosphorylated tau, and their use
US6881557B2 (en)	2001-07-12	2005-04-19	Arrowsmith Technologies Llp	Super humanized antibodies
US7657380B2 (en)	2003-12-04	2010-02-02	Xencor, Inc.	Methods of generating variant antibodies with increased host string content
US20070048785A1 (en)	2004-06-09	2007-03-01	Lin Laura L	Anti-IL-13 antibodies and complexes
EP1790664A1 (en)	2005-11-24	2007-05-30	Ganymed Pharmaceuticals AG	Monoclonal antibodies against claudin-18 for treatment of cancer
US20070280935A1 (en) *	2006-04-07	2007-12-06	Bernd Bohrmann	Antibody that recognizes phosphorylated peptides
EP2420252A1 (en) *	2006-08-04	2012-02-22	Novartis AG	EPHB3-specific antibody and uses thereof
JP2010235447A (ja) *	2007-07-30	2010-10-21	Igaku Seibutsugaku Kenkyusho:Kk	炎症性サイトカインの抑制剤
JP2012505654A (ja)	2008-10-14	2012-03-08	ヤンセンバイオテツク，インコーポレーテツド	抗体をヒト化及び親和性成熟する方法
US9968574B2 (en) *	2009-05-15	2018-05-15	The University Of Kentucky Research Foundation	Treatment of MCI and Alzheimer's disease
US8609097B2 (en) *	2009-06-10	2013-12-17	Hoffmann-La Roche Inc.	Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP3329932A1 (en)	2009-06-10	2018-06-06	New York University	Immunological targeting of pathological tau proteins
US8912355B2 (en) *	2009-09-29	2014-12-16	University Of Ottawa Heart Institute	Linoleic phospholipids and uses thereof for inhibiting inflammatory and neurodegenerative processes
WO2011047146A2 (en)	2009-10-14	2011-04-21	Centocor Ortho Biotech Inc.	Methods of affinity maturing antibodies
PE20140218A1 (es) *	2010-10-07	2014-03-01	Ac Inmune S A	Composicion farmaceutica
MX345092B (es) *	2010-10-11	2017-01-17	Univ Zuerich	Anticuerpos anti-tau humanos,.
EP2794654B1 (en) *	2011-12-20	2019-05-22	Janssen Biotech, Inc.	Anti-phf-tau antibodies and their uses

2012
- 2012-12-19 EP EP12859920.6A patent/EP2794654B1/en active Active
- 2012-12-19 TR TR2019/10720T patent/TR201910720T4/tr unknown
- 2012-12-19 RS RS20190932A patent/RS59024B1/sr unknown
- 2012-12-19 KR KR1020147019911A patent/KR101991681B1/ko active IP Right Grant
- 2012-12-19 PT PT12859920T patent/PT2794654T/pt unknown
- 2012-12-19 WO PCT/US2012/070486 patent/WO2013096380A2/en active Application Filing
- 2012-12-19 EP EP19173615.6A patent/EP3578567A1/en active Pending
- 2012-12-19 LT LT12859920T patent/LT2794654T/lt unknown
- 2012-12-19 SI SI201231610T patent/SI2794654T1/sl unknown
- 2012-12-19 MX MX2014007476A patent/MX350311B/es active IP Right Grant
- 2012-12-19 AU AU2012359039A patent/AU2012359039B2/en active Active
- 2012-12-19 US US14/363,888 patent/US9371376B2/en active Active
- 2012-12-19 UA UAA201408042A patent/UA114902C2/uk unknown
- 2012-12-19 HU HUE12859920A patent/HUE045656T2/hu unknown
- 2012-12-19 SG SG11201403106SA patent/SG11201403106SA/en unknown
- 2012-12-19 CA CA3234629A patent/CA3234629A1/en active Pending
- 2012-12-19 JP JP2014548811A patent/JP6306513B2/ja active Active
- 2012-12-19 CN CN201710472573.8A patent/CN107226863B/zh active Active
- 2012-12-19 MY MYPI2017000364A patent/MY186066A/en unknown
- 2012-12-19 BR BR112014015323-0A patent/BR112014015323B1/pt active IP Right Grant
- 2012-12-19 EA EA201491224A patent/EA027975B1/ru not_active IP Right Cessation
- 2012-12-19 NZ NZ626269A patent/NZ626269A/en unknown
- 2012-12-19 CN CN201280062971.8A patent/CN104024274B/zh active Active
- 2012-12-19 DK DK12859920.6T patent/DK2794654T3/da active
- 2012-12-19 MY MYPI2014701643A patent/MY178142A/en unknown
- 2012-12-19 PL PL12859920T patent/PL2794654T3/pl unknown
- 2012-12-19 CA CA2859665A patent/CA2859665C/en active Active
- 2012-12-19 ES ES12859920T patent/ES2738007T3/es active Active
2014
- 2014-06-10 IL IL233051A patent/IL233051B/en active IP Right Grant
- 2014-06-19 NI NI201400061A patent/NI201400061A/es unknown
- 2014-06-20 CO CO14134449A patent/CO6980627A2/es unknown
- 2014-06-20 GT GT201400127A patent/GT201400127A/es unknown
- 2014-06-20 EC ECIEPI20145975A patent/ECSP14005975A/es unknown
- 2014-06-20 PH PH12014501427A patent/PH12014501427B1/en unknown
- 2014-07-18 ZA ZA2014/05317A patent/ZA201405317B/en unknown
2015
- 2015-04-24 HK HK15103967.6A patent/HK1203520A1/xx unknown
2016
- 2016-04-26 US US15/138,635 patent/US9745371B2/en active Active
2017
- 2017-07-11 US US15/646,865 patent/US10000559B2/en active Active
- 2017-11-20 AU AU2017264975A patent/AU2017264975B2/en active Active
- 2017-12-21 JP JP2017245019A patent/JP6695317B2/ja active Active
2018
- 2018-03-07 HK HK18103213.5A patent/HK1244490A1/zh unknown
- 2018-05-21 US US15/984,772 patent/US10196440B2/en active Active
- 2018-11-14 IL IL263021A patent/IL263021B/en active IP Right Grant
2019
- 2019-06-10 JP JP2019108147A patent/JP6987809B2/ja active Active
- 2019-07-25 HR HRP20191342 patent/HRP20191342T1/hr unknown
- 2019-08-06 CY CY20191100834T patent/CY1121862T1/el unknown
2020
- 2020-02-10 JP JP2020020482A patent/JP6987904B2/ja active Active
2021
- 2021-03-03 IL IL281250A patent/IL281250A/en unknown

Also Published As

Publication number	Publication date
JP6987904B2 (ja)	2022-01-05
SG11201403106SA (en)	2014-12-30
WO2013096380A3 (en)	2013-08-22
US20170355758A1 (en)	2017-12-14
JP2015500879A (ja)	2015-01-08
IL281250A (en)	2021-04-29
US20160304593A1 (en)	2016-10-20
CN104024274B (zh)	2017-07-18
EA201491224A1 (ru)	2014-11-28
NZ626269A (en)	2016-06-24
US9745371B2 (en)	2017-08-29
CN107226863B (zh)	2021-06-01
GT201400127A (es)	2015-03-23
JP2018078897A (ja)	2018-05-24
AU2017264975B2 (en)	2019-09-12
AU2012359039B2 (en)	2017-08-24
TR201910720T4 (tr)	2019-08-21
JP6695317B2 (ja)	2020-05-20
MX2014007476A (es)	2014-07-28
CA2859665A1 (en)	2013-06-27
US20180305445A1 (en)	2018-10-25
CN104024274A (zh)	2014-09-03
NZ720141A (en)	2017-09-29
ES2738007T3 (es)	2020-01-17
JP2019176866A (ja)	2019-10-17
JP6306513B2 (ja)	2018-04-04
HK1203520A1 (en)	2015-10-30
MY186066A (en)	2021-06-18
IL263021A (en)	2018-12-31
IL233051B (en)	2019-02-28
EA027975B1 (ru)	2017-09-29
IL263021B (en)	2021-03-25
CN107226863A (zh)	2017-10-03
MX350311B (es)	2017-09-01
WO2013096380A2 (en)	2013-06-27
JP2020105179A (ja)	2020-07-09
RS59024B1 (sr)	2019-08-30
EP2794654A4 (en)	2015-09-30
NI201400061A (es)	2016-12-02
BR112014015323A2 (pt)	2020-10-27
US20150307600A1 (en)	2015-10-29
JP6987809B2 (ja)	2022-01-05
US10196440B2 (en)	2019-02-05
PH12014501427A1 (en)	2014-09-22
CO6980627A2 (es)	2014-06-27
ZA201405317B (en)	2016-05-25
SI2794654T1 (sl)	2019-08-30
HRP20191342T1 (hr)	2019-11-01
EP2794654A2 (en)	2014-10-29
MY178142A (en)	2020-10-05
AU2012359039A1 (en)	2014-07-03
CA3234629A1 (en)	2013-06-27
KR101991681B1 (ko)	2019-06-21
IL233051A0 (en)	2014-07-31
EP2794654B1 (en)	2019-05-22
UA114902C2 (uk)	2017-08-28
HUE045656T2 (hu)	2020-01-28
PL2794654T3 (pl)	2019-11-29
LT2794654T (lt)	2019-11-11
KR20140107493A (ko)	2014-09-04
EP3578567A1 (en)	2019-12-11
CY1121862T1 (el)	2020-07-31
ECSP14005975A (es)	2015-07-31
DK2794654T3 (da)	2019-08-05
HK1244490A1 (zh)	2018-08-10
US9371376B2 (en)	2016-06-21
PH12014501427B1 (en)	2014-09-22
AU2017264975A1 (en)	2017-12-21
CA2859665C (en)	2024-05-21
BR112014015323B1 (pt)	2022-09-27
US10000559B2 (en)	2018-06-19

Publication	Publication Date	Title
IL281250A (en)	2021-04-29	Anti-PHF-tau antibodies and uses thereof
HUS2100034I1 (hu)	2021-10-28	ANGPTL3-ellenes antitestek és alkalmazásaik
IL288203A (en)	2022-01-01	Meditops and Meditop binding antibodies and their use
HUS2000056I1 (hu)	2021-03-01	ANTI-PD-L1 ellenanyagok és alkalmazásaik
IL232399A0 (en)	2014-06-30	Anti-2fgfr antibodies and their use
EP2756094A4 (en)	2015-05-06	ANTI-B7-H4 ANTIBODIES AND USES THEREOF
HK1207092A1 (en)	2016-01-22	Anti-hla-b27 antibodies and uses thereof -hla-b27
DK2729170T3 (en)	2022-03-21	Antibody variants and uses thereof
HK1199842A1 (en)	2015-07-24	Anti-siglec-15 antibodies and uses thereof -15
EP2668210A4 (en)	2015-09-02	ANTI-KIT ANTIBODIES AND ITS USES
HK1199269A1 (en)	2015-06-26	Anti-asic1 antibodies and uses thereof -asic1